Effect of ribavirin on viral shedding and mortality among 55 patients with PIV-3 LRI.

(A) Duration of PIV-3 shedding from the nasopharynx was similar for patients who did (░) and who did not (▪) receive aerosolized ribavirin. (B) The 30-day mortality with PIV-3 LRI, stratified by presence of copathogens and no treatment (░), treatment with ribavirin (▪), and treatment with ribavirin and IVIG (▤). Mortality rates were comparable for all treatment groups and were influenced by copathogen status.